MedTrace Logo

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

NCT03369301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2022-03-02

No results posted yet for this study

Summary

Patients with Myeloma or CLL with severe secondary hypogammaglobinemia and recurrent infections will be included in this study; for whom an IgSC treatment was prescribed. The IgSC prescription will be the decision of the treating physician. Patient care and follow up will be performed according to the current clinical practice and the recommendations of HAS.

Conditions

  • Secondary Immune Deficiency

Interventions

DRUG

Gammanorm

Gammanorm given per standard of care

DRUG

Other Subcutaneous Immunoglobulins

Other Subcutaneous Immunoglobulins given per standard of care

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2019-11-22
Completion
2019-11-22
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03369301 on ClinicalTrials.gov